You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Name19-norandrostenedione
Accession NumberDB01434
TypeSmall Molecule
GroupsExperimental, Illicit
Description19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. In the body 19-norandrostenedione is rapidly metabolized into nandrolone, also known as nortestosterone.
Structure
Thumb
Synonyms
4-estrene-3,17-dione
delta4-Estrene-3,17-dione
NOR
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
19-N-AndroNot Available
BolandioneNot Available
Proven Pure 19-NorandrostenedioneNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIU90987PVU5
CAS number734-32-7
WeightAverage: 272.382
Monoisotopic: 272.177630012
Chemical FormulaC18H24O2
InChI KeyJRIZOGLBRPZBLQ-QXUSFIETSA-N
InChI
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-16H,2-9H2,1H3/t13-,14+,15+,16-,18-/m0/s1
IUPAC Name
(1S,2R,10R,11S,15S)-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-5,14-dione
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Pharmacology
IndicationThe claim that supplemental 19-norandrostenedione has anabolic effects is unsubstantiated.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action19-Norandrostenedione may be metabolized to 19-nortestosterone in both men and women. 19-Norandrostenedione, also known as nandrolone, is the basic substance of some very popular injectable anabolic steroids, however 19-norandrostenedione is not metabolized to testosterone. Whether or not increases in 19-nortestosterone levels would be sustained long enough by taking 19-norandrostenedione to show an increase in nitrogen retention and muscle strength and mass is unknown. 19-Norandrostenedione has also been shown to bind to androgen receptors with high selectivity. Transactivation of androgen receptor dependent reporter gene expression was 10 times lower than that produced by dihydrotestosterone. [1]
Related Articles
AbsorptionAbsorption appears variable, but some absorption does occur.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Specific metabolites of 19-nor-5-androstene-3, 17-dione are 19-nordehydroandrosterone and 19-nordehydroepiandrosterone.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with 19-norandrostenedione.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with 19-norandrostenedione.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 19-norandrostenedione.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with 19-norandrostenedione.Approved
Aldesleukin19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 19-norandrostenedione.Approved
AmiodaroneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin B19-norandrostenedione may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with 19-norandrostenedione.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with 19-norandrostenedione.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with 19-norandrostenedione.Approved, Investigational
AprepitantThe serum concentration of 19-norandrostenedione can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of 19-norandrostenedione.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with 19-norandrostenedione.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with 19-norandrostenedione.Approved, Investigational
BazedoxifeneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Bazedoxifene.Approved, Investigational
Bendroflumethiazide19-norandrostenedione may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with 19-norandrostenedione.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with 19-norandrostenedione.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with 19-norandrostenedione.Investigational
Bismuth SubcitrateThe bioavailability of 19-norandrostenedione can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with 19-norandrostenedione.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with 19-norandrostenedione.Investigational
Bumetanide19-norandrostenedione may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 19-norandrostenedione.Approved, Nutraceutical
Calcium carbonateThe bioavailability of 19-norandrostenedione can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with 19-norandrostenedione.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with 19-norandrostenedione.Experimental
CDX-110The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with 19-norandrostenedione.Approved, Investigational
Ceritinib19-norandrostenedione may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with 19-norandrostenedione.Approved, Vet Approved
Chlorothiazide19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Chlorotrianisene.Withdrawn
Chlorthalidone19-norandrostenedione may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with 19-norandrostenedione.Approved
CobicistatThe serum concentration of 19-norandrostenedione can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of 19-norandrostenedione can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 19-norandrostenedione.Approved
CoumaphosThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with 19-norandrostenedione.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with 19-norandrostenedione.Investigational
DarunavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with 19-norandrostenedione.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with 19-norandrostenedione.Approved, Vet Approved
DienestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with 19-norandrostenedione.Approved
Dihydrotestosterone19-norandrostenedione may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with 19-norandrostenedione.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with 19-norandrostenedione.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with 19-norandrostenedione.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with 19-norandrostenedione.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with 19-norandrostenedione.Approved
EstradiolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estrone.Approved
Etacrynic acid19-norandrostenedione may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with 19-norandrostenedione.Approved, Investigational
Ethinyl EstradiolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with 19-norandrostenedione.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with 19-norandrostenedione.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 19-norandrostenedione.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with 19-norandrostenedione.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with 19-norandrostenedione.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with 19-norandrostenedione.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with 19-norandrostenedione.Approved
FenthionThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with 19-norandrostenedione.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with 19-norandrostenedione.Vet Approved
Fluoxymesterone19-norandrostenedione may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with 19-norandrostenedione.Approved, Investigational
FosaprepitantThe serum concentration of 19-norandrostenedione can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Fosphenytoin.Approved
Furosemide19-norandrostenedione may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with 19-norandrostenedione.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with 19-norandrostenedione.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with 19-norandrostenedione.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 19-norandrostenedione.Approved, Investigational
Hydrochlorothiazide19-norandrostenedione may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydroflumethiazide19-norandrostenedione may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with 19-norandrostenedione.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with 19-norandrostenedione.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with 19-norandrostenedione.Approved
IdelalisibThe serum concentration of 19-norandrostenedione can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of 19-norandrostenedione.Approved
Indapamide19-norandrostenedione may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with 19-norandrostenedione.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with 19-norandrostenedione.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with 19-norandrostenedione.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with 19-norandrostenedione.Withdrawn
ItraconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with 19-norandrostenedione.Experimental
KetoconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with 19-norandrostenedione.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with 19-norandrostenedione.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with 19-norandrostenedione.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 19-norandrostenedione.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with 19-norandrostenedione.Approved
LumacaftorThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with 19-norandrostenedione.Approved, Investigational
MagaldrateThe bioavailability of 19-norandrostenedione can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione.Approved
Magnesium TrisilicateThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with 19-norandrostenedione.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with 19-norandrostenedione.Approved
MefloquineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with 19-norandrostenedione.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with 19-norandrostenedione.Approved
MestranolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with 19-norandrostenedione.Withdrawn
MethallenestrilThe serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Methanesulfonyl Fluoride.Investigational
Methyclothiazide19-norandrostenedione may increase the hypokalemic activities of Methyclothiazide.Approved
Methyltestosterone19-norandrostenedione may increase the fluid retaining activities of Methyltestosterone.Approved
Metolazone19-norandrostenedione may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of 19-norandrostenedione can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Minaprine.Approved
MitotaneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with 19-norandrostenedione.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 19-norandrostenedione.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 19-norandrostenedione.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 19-norandrostenedione.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with 19-norandrostenedione.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with 19-norandrostenedione.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with 19-norandrostenedione.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with 19-norandrostenedione.Investigational
NefazodoneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with 19-norandrostenedione.Approved
NevirapineThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 19-norandrostenedione.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with 19-norandrostenedione.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with 19-norandrostenedione.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with 19-norandrostenedione.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with 19-norandrostenedione.Vet Approved
Oxandrolone19-norandrostenedione may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 19-norandrostenedione.Approved
Oxymetholone19-norandrostenedione may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 19-norandrostenedione.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with 19-norandrostenedione.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with 19-norandrostenedione.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with 19-norandrostenedione.Approved, Vet Approved
PhenytoinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 19-norandrostenedione.Approved, Investigational
Piretanide19-norandrostenedione may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 19-norandrostenedione.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with 19-norandrostenedione.Approved, Investigational
Polyestradiol phosphateThe serum concentration of 19-norandrostenedione can be increased when it is combined with Polyestradiol phosphate.Approved
Polythiazide19-norandrostenedione may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with 19-norandrostenedione.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with 19-norandrostenedione.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Quinestrol.Approved
Quinethazone19-norandrostenedione may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of 19-norandrostenedione.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione.Experimental, Investigational
RifabutinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with 19-norandrostenedione.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rosoxacin.Approved
S EquolThe serum concentration of 19-norandrostenedione can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with 19-norandrostenedione.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with 19-norandrostenedione.Approved
SaquinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with 19-norandrostenedione.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with 19-norandrostenedione.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with 19-norandrostenedione.Investigational
St. John's WortThe serum concentration of 19-norandrostenedione can be decreased when it is combined with St. John's Wort.Nutraceutical
Stanozolol19-norandrostenedione may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with 19-norandrostenedione.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with 19-norandrostenedione.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with 19-norandrostenedione.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with 19-norandrostenedione.Approved
TelithromycinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with 19-norandrostenedione.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with 19-norandrostenedione.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with 19-norandrostenedione.Approved
Testosterone19-norandrostenedione may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 19-norandrostenedione.Approved
TiboloneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with 19-norandrostenedione.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 19-norandrostenedione.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with 19-norandrostenedione.Approved
Torasemide19-norandrostenedione may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with 19-norandrostenedione.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trichlorfon.Vet Approved
Trichlormethiazide19-norandrostenedione may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with 19-norandrostenedione.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 19-norandrostenedione.Investigational, Withdrawn
VoriconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Voriconazole.Approved, Investigational
Warfarin19-norandrostenedione may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione.Approved
ZeranolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with 19-norandrostenedione.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with 19-norandrostenedione.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Diel P, Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schanzer W, Schleipen B, Thevis M, Vollmer G, Zierau O: The prohormone 19-norandrostenedione displays selective androgen receptor modulator (SARM) like properties after subcutaneous administration. Toxicol Lett. 2008 Apr 1;177(3):198-204. doi: 10.1016/j.toxlet.2008.01.014. Epub 2008 Feb 2. [PubMed:18325697 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9723
Caco-2 permeable+0.7785
P-glycoprotein substrateSubstrate0.5551
P-glycoprotein inhibitor IInhibitor0.8097
P-glycoprotein inhibitor IINon-inhibitor0.6972
Renal organic cation transporterNon-inhibitor0.638
CYP450 2C9 substrateNon-substrate0.827
CYP450 2D6 substrateNon-substrate0.9064
CYP450 3A4 substrateSubstrate0.6816
CYP450 1A2 substrateNon-inhibitor0.8259
CYP450 2C9 inhibitorNon-inhibitor0.9269
CYP450 2D6 inhibitorNon-inhibitor0.94
CYP450 2C19 inhibitorNon-inhibitor0.7094
CYP450 3A4 inhibitorNon-inhibitor0.8652
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7931
Ames testNon AMES toxic0.9189
CarcinogenicityNon-carcinogens0.9403
BiodegradationNot ready biodegradable0.9401
Rat acute toxicity1.6104 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7011
hERG inhibition (predictor II)Non-inhibitor0.7574
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0454 mg/mLALOGPS
logP2.53ALOGPS
logP3.63ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)19.19ChemAxon
pKa (Strongest Basic)-4.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.13 m3·mol-1ChemAxon
Polarizability31.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrogens and derivatives
Alternative Parents
Substituents
  • Estrogen-skeleton
  • Oxosteroid
  • 17-oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Cyclic ketone
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available
Comments
comments powered by Disqus
Drug created on July 24, 2007 14:36 / Updated on August 17, 2016 12:23